MX2010005999A - Intermediarios en la sintesis de analogos de macrolidos de zearalenona. - Google Patents

Intermediarios en la sintesis de analogos de macrolidos de zearalenona.

Info

Publication number
MX2010005999A
MX2010005999A MX2010005999A MX2010005999A MX2010005999A MX 2010005999 A MX2010005999 A MX 2010005999A MX 2010005999 A MX2010005999 A MX 2010005999A MX 2010005999 A MX2010005999 A MX 2010005999A MX 2010005999 A MX2010005999 A MX 2010005999A
Authority
MX
Mexico
Prior art keywords
intermediates
synthesis
zearalenone
macrolide analogs
analogs
Prior art date
Application number
MX2010005999A
Other languages
English (en)
Inventor
Francis G Fang
Xiang Niu
Matthew J Schnaderbeck
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2010005999A publication Critical patent/MX2010005999A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/081,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Cosmetics (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen aquí métodos e intermediarios útiles en la preparación de macrólidos, por ejemplo, compuestos de la fórmula (IV), (ver fórmula IV) en donde R1-R22 son como se definen aquí.
MX2010005999A 2007-12-07 2008-12-08 Intermediarios en la sintesis de analogos de macrolidos de zearalenona. MX2010005999A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1240907P 2007-12-07 2007-12-07
US1240807P 2007-12-07 2007-12-07
US1241107P 2007-12-07 2007-12-07
US8004808P 2008-07-11 2008-07-11
PCT/US2008/013512 WO2009075823A1 (en) 2007-12-07 2008-12-08 Intermediates in the synthesis of zearalenone macrolide analogs

Publications (1)

Publication Number Publication Date
MX2010005999A true MX2010005999A (es) 2010-06-23

Family

ID=40445478

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010005999A MX2010005999A (es) 2007-12-07 2008-12-08 Intermediarios en la sintesis de analogos de macrolidos de zearalenona.
MX2010006091A MX2010006091A (es) 2007-12-07 2008-12-08 Intermediarios y metodos para hacer analogos de macrolido de zearalenona.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010006091A MX2010006091A (es) 2007-12-07 2008-12-08 Intermediarios y metodos para hacer analogos de macrolido de zearalenona.

Country Status (10)

Country Link
US (3) US8507696B2 (es)
EP (2) EP2231635B1 (es)
JP (3) JP5496908B2 (es)
CN (2) CN101889005B (es)
BR (2) BRPI0820958B1 (es)
CA (2) CA2708143C (es)
IL (2) IL205954A (es)
MX (2) MX2010005999A (es)
RU (2) RU2497803C2 (es)
WO (2) WO2009075823A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076424A1 (en) 2002-03-08 2003-09-18 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
ES2670423T3 (es) 2007-07-25 2018-05-30 Eisai R&D Management Co., Ltd. Inhibidores de multicinasas para uso en el tratamiento de cáncer
EP2231635B1 (en) 2007-12-07 2014-03-19 Eisai R&D Management Co., Ltd. Intermediates and methods for making zearalenone macrolide analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69666A (en) * 1982-09-13 1987-10-20 Lilly Co Eli 20-amino-20-deoxo-5-o-mycaminosyl-23-o-mycinosyltylonolide derivatives,their preparation and veterinary antibiotic use
GB9225396D0 (en) 1992-12-04 1993-01-27 Sandoz Ltd Improvements in or relating to organic compounds
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
SK286592B6 (sk) * 1997-07-08 2009-01-07 Bristol-Myers Squibb Company Derivát epotilónu, farmaceutický prostriedok s jeho obsahom a jeho použitie
JP2004292314A (ja) 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd ケラチノサイト増殖抑制剤
JP2004292315A (ja) 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd Tak1阻害剤
WO2003076424A1 (en) * 2002-03-08 2003-09-18 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
US7915306B2 (en) 2002-03-08 2011-03-29 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
US8067412B2 (en) 2006-08-11 2011-11-29 Universite De Strasbourg Macrocyclic compounds useful as inhibitors of kinases and HSP90
US8513440B2 (en) * 2007-06-05 2013-08-20 Universite De Strasbourg Compositions and methods comprising analogues of radicicol A
ES2670423T3 (es) 2007-07-25 2018-05-30 Eisai R&D Management Co., Ltd. Inhibidores de multicinasas para uso en el tratamiento de cáncer
TW200924749A (en) * 2007-07-25 2009-06-16 Eisai R & Amp D Man Co Ltd Zearalenone macrolide derivatives and uses of the same
EP2231635B1 (en) 2007-12-07 2014-03-19 Eisai R&D Management Co., Ltd. Intermediates and methods for making zearalenone macrolide analogs

Also Published As

Publication number Publication date
CA2708143A1 (en) 2009-06-18
EP2231635A1 (en) 2010-09-29
JP2014141498A (ja) 2014-08-07
CA2708141A1 (en) 2009-06-18
CA2708143C (en) 2016-10-11
BRPI0820953B1 (pt) 2022-04-05
RU2497803C2 (ru) 2013-11-10
US8507696B2 (en) 2013-08-13
US20130211103A1 (en) 2013-08-15
WO2009075823A1 (en) 2009-06-18
RU2478630C2 (ru) 2013-04-10
US20110046398A1 (en) 2011-02-24
IL205983A (en) 2017-01-31
CA2708141C (en) 2016-07-05
JP2011506324A (ja) 2011-03-03
MX2010006091A (es) 2010-06-25
IL205954A0 (en) 2010-11-30
BRPI0820958A2 (pt) 2015-07-07
CN101889006A (zh) 2010-11-17
JP5492786B2 (ja) 2014-05-14
CN101889005A (zh) 2010-11-17
JP5496908B2 (ja) 2014-05-21
US8350059B2 (en) 2013-01-08
IL205983A0 (en) 2010-11-30
BRPI0820953A2 (pt) 2015-06-23
US20110237805A1 (en) 2011-09-29
RU2010128096A (ru) 2012-01-20
EP2231634A1 (en) 2010-09-29
JP2011506323A (ja) 2011-03-03
CN101889005B (zh) 2015-06-03
EP2231635B1 (en) 2014-03-19
CN101889006B (zh) 2013-09-04
EP2231634B1 (en) 2016-05-11
WO2009075818A1 (en) 2009-06-18
IL205954A (en) 2017-01-31
BRPI0820958B1 (pt) 2022-04-05
RU2010128103A (ru) 2012-01-20

Similar Documents

Publication Publication Date Title
MX343042B (es) Compuestos heteroarilicos biciclicos.
NZ588884A (en) Cross-linkers and their uses
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
TW200745149A (en) Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments
MX2010004234A (es) Derivados de purina como ligandos del receptor de adenosina a1.
SG150518A1 (en) Macrolides and methods for producing same
MX2010009646A (es) Agentes terapeuticos antivirales.
MX2010003599A (es) Intermediarios y metodos para la sintesis de analogos de halicondrina b.
GB0508318D0 (en) Organic compounds
WO2007133560A3 (en) Acetylenic heteroaryl compounds
AU2007249926A8 (en) Monocyclic heteroaryl compounds
GB0508314D0 (en) Organic compounds
TW200740814A (en) Compounds
IL265947A (en) Preparation of stansoporfin with a high degree of purification on a large scale
TW200800986A (en) Tetrahydroquinolines, synthesis thereof, and intermediates thereto
TW200738713A (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
MX2010005999A (es) Intermediarios en la sintesis de analogos de macrolidos de zearalenona.
WO2009062659A3 (en) Polymorphs of enantiopure erdosteine
MX2009009074A (es) Macrolidos basados en eritromicina.
WO2008107771A3 (en) 2',3'-di-o-acyl-5-fluoronucleosides
HK1131156A1 (en) Novel morphine derivatives
MX2010003056A (es) Polimorfos de valomaciclovir.
WO2007098462A3 (en) Trans-fused chromenoisoquinolines, synthesis and methods for use
NZ593021A (en) Method of preparing deoxyribofuranose compounds
WO2010139411A3 (de) 17β-ALKYL-17α-OXY-ESTRATRIENE

Legal Events

Date Code Title Description
FG Grant or registration